Evolus Inc. Common Stock (EOLS)

FairStock Score: 31/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn consistent profits, generate free cash, and have a durable competitive advantage. Evolus is not there yet. It sells Jeuveau and Evolysse in the cash-pay aesthetic market. Revenue is growing: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $84.1 million, up from $69.4 million in fiscal Q2 2025, and the net loss narrowed to $8.1 million from $17.1 million. For FY2025, revenue was $297.2 million, but net loss was $51.6 million. At the 2026-10-13 close of $7.51, market cap was $496.0 million and the FairStock-calculated P/E was -14.17. Trailing free cash flow was -$21.9 million, a -4.4% FCF yield. ROCE was -5.68%. The Piotroski F-Score was 5/9 and the Altman Z-Score was -2.14, suggesting middling progress and financial strain. The computed Lynch category is none because it lost money in each of the last four years. FY2023 net loss was $61.7 million, FY2024 was $50.4 million, and FY2025 was $51.6 million. Revenue growth is real, but the bottom line has not turned. Against FY2025 sales, the market pays about 1.7 times revenue. That could be justified if losses keep shrinking and cash flow turns positive, but there is no earnings-based margin of safety. The 52-week range of $3.86 to $9.31 and beta of 1.34 show the market has repriced it widely. The FairStock Score is 31/100. I would want to see positive free cash flow and consistent profits before calling this a durable compounder. For now, it is a speculative growth story, not a proven value investment.

In plain English: Evolus sells cosmetic injectables such as Jeuveau for frown lines and Evolysse fillers. Sales are growing, but the company still loses money and burns cash. At $7.51 a share, the price is not cheap based on current profits because there are no profits; it depends on future growth.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer